The international surgical journal with global reach

Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020; 9: 1129.

Published: 22nd July 2020

Authors: Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A et al.

Conclusion

There were six RCTs that included 850 patients. Neoadjuvant therapy (NT) improved overall survival (hazard ratio 0.73, 95 per cent confidence interval 0.61 to 0.86), regardless of type of pancreatic cancer, or whether chemotherapy or radiotherapy was used. NT increased the chance of margin negative resection.

Pubmed Link